These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 27998592)

  • 1. Motavizumab, RSV, and subsequent wheezing - Authors' reply.
    O'Brien KL; Driscoll AJ; Santosham M; Hammitt LL; Karron RA
    Lancet Infect Dis; 2016 Dec; 16(12):1329-1330. PubMed ID: 27998592
    [No Abstract]   [Full Text] [Related]  

  • 2. Motavizumab, RSV, and subsequent wheezing.
    Simões EAF
    Lancet Infect Dis; 2016 Jun; 16(6):639-640. PubMed ID: 27301921
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
    Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
    Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
    Lagos R; DeVincenzo JP; Muñoz A; Hultquist M; Suzich J; Connor EM; Losonsky GA
    Pediatr Infect Dis J; 2009 Sep; 28(9):835-7. PubMed ID: 19636278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
    Yoshihara S; Kusuda S; Mochizuki H; Okada K; Nishima S; Simões EA;
    Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
    Feltes TF; Sondheimer HM; Tulloh RM; Harris BS; Jensen KM; Losonsky GA; Griffin MP;
    Pediatr Res; 2011 Aug; 70(2):186-91. PubMed ID: 21522037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Authors' response re: Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.
    Meissner HC; Kimberlin DW
    Pediatrics; 2014 Apr; 133(4):e1101-3. PubMed ID: 24692038
    [No Abstract]   [Full Text] [Related]  

  • 10. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
    Blanken M; Rovers M; Sanders E; Bont L
    Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
    Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
    N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus infection is linked to recurrent wheezing in healthy premature infants.
    Escobar GJ
    J Pediatr; 2013 Nov; 163(5):1531. PubMed ID: 24160662
    [No Abstract]   [Full Text] [Related]  

  • 13. Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up.
    Valkonen H; Waris M; Ruohola A; Ruuskanen O; Heikkinen T
    Allergy; 2009 Sep; 64(9):1359-65. PubMed ID: 19416146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
    Weisman LE
    Curr Opin Mol Ther; 2009 Apr; 11(2):208-18. PubMed ID: 19330726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia.
    Shi X; Zheng J; Yan T
    J Mol Model; 2018 Mar; 24(4):79. PubMed ID: 29500665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
    Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA
    J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RSV immunoprophylaxis: does the benefit justify the cost?
    Meissner HC; Kimberlin DW
    Pediatrics; 2013 Nov; 132(5):915-8. PubMed ID: 24127478
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody against RSV helps prevent wheeze in infants.
    BMJ; 2013 May; 346():f3089. PubMed ID: 23678095
    [No Abstract]   [Full Text] [Related]  

  • 19. Wheezing illness caused by respiratory syncytial virus and other agents.
    Yasuno T; Shimizu T; Maeda Y; Yamasaki A; Amaya E; Kawakatsu H
    Pediatr Int; 2008 Aug; 50(4):500-5. PubMed ID: 18937754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
    J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.